Arixtra and Neutrophil count increased - a phase IV clinical study of FDA data

Summary:

Neutrophil count increased is reported as a side effect among people who take Arixtra (fondaparinux sodium), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Mcp, and have Analgesia.

The phase IV clinical study analyzes which people have Neutrophil count increased when taking Arixtra. It is created by eHealthMe based on reports of 9,755 people who have side effects when taking Arixtra from the FDA, and is updated regularly.

What is Arixtra?

Arixtra has active ingredients of fondaparinux sodium. It is often used in deep venous thrombosis. eHealthMe is studying from 9,830 Arixtra users. Check the latest studies of Arixtra.

What is Neutrophil count increased?

Neutrophil count increased (excess than normal number of neutrophil a type of blood cell) is found to be associated with 943 drugs and 1,169 conditions by eHealthMe. Check the latest studies of Neutrophil count increased.

On Aug, 02, 2026

9,755 people reported to have side effects when taking Arixtra.
Among them, 13 people (0.13%) have Neutrophil count increased.

Could Arixtra cause Neutrophil count increased?

Among these 13 people:

How long have people been on Arixtra when they have Neutrophil count increased? *

What is the gender of people who have Neutrophil count increased when taking Arixtra? *

female: 46.15 %
male: 53.85 %

What is the age of people who have Neutrophil count increased when taking Arixtra? *

What are other drugs people take besides Arixtra? *

What are other side effects people have besides Neutrophil count increased? *

Haemoglobin Decreased: 10 people, 76.92%
White Blood Cell Count Increased: 8 people, 61.54%
Haematocrit Decreased: 8 people, 61.54%
Red Blood Cell Count Decreased: 7 people, 53.85%
Lymphocyte Count Decreased: 7 people, 53.85%
Platelet Count Increased: 6 people, 46.15%
C-Reactive Protein Increased: 4 people, 30.77%
Blood Glucose Increased: 4 people, 30.77%
High Density Lipoprotein Increased: 3 people, 23.08%
Nausea And Vomiting: 3 people, 23.08%

What are the existing conditions these people have? *

Analgesia: 5 people, 38.46%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 2 people, 15.38%
Pulmonary Embolism (blockage of the main artery of the lung): 2 people, 15.38%
Polyneuropathy Alcoholic (neurological disorder that occurs when many peripheral nerves throughout the body malfunction simultaneously due to alcohol): 2 people, 15.38%
Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 2 people, 15.38%
Malignant Melanoma (skin cancer rises from melancytes): 2 people, 15.38%
Hyperlipidaemia (presence of excess lipids in the blood): 2 people, 15.38%
Depression: 2 people, 15.38%
Thrombosis (formation of a blood clot inside a blood vessel): 1 person, 7.69%
Rashes (redness): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Arixtra and have Neutrophil count increased?

- Check whether Neutrophil count increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Arixtra:

Arixtra (9,830 reports)

Browse all side effects of Arixtra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Neutrophil count increased:

Neutrophil count increased (943 drugs)

Browse all the conditions that are associated with Neutrophil count increased:

Neutrophil count increased (1,169 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on fondaparinux sodium (the active ingredients of Arixtra) and Arixtra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.